After the company’s common stock ceased trading on the OTCQX when the market closed yesterday, it began trading on the NYSE at the open of trading today, under the same “STXS” symbol.
The St. Louis, Mo.-based company specializes in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
“We are excited to list on the NYSE American,” Stereotaxis chairman & CEO David Fischel said in a release. “This is another milestone in our effort to improve awareness of our differentiated technology, clinical value, and growth opportunity. Listing on the NYSE American should support a more robust capital market for existing and new shareholders.”
In May, Stereotaxis launched the Genesis RMN robotic navigation and imaging device and announced a collaborative deal with Osypka AG. Stereotaxis claims that Genesis RMN’s mechanism allows for instantaneous responsiveness and flexibility for an increased range of motion. The Genesis RMN system is also significantly reduced in size, the company said.
The deal with Rheinfelden, Germany-based Osypka is to design and develop a next-generation magnetic ablation catheter intended for use with Stereotaxis’ robotic technology.
Shares of STXS on the NYSE remained unchanged in mid-afternoon trading today.